ARGX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 15.95% compared to argenx SE's net margin of --. argenx SE's return on equity of -6.01% beat DBV Technologies SA's return on equity of --.

argenx SE has a consensus price target of $655.15, signalling upside risk potential of 3.66%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 638.66%. Given that DBV Technologies SA has higher upside potential than argenx SE, analysts believe DBV Technologies SA is more attractive than argenx SE.

argenx SE has a beta of 0.589, which suggesting that the stock is 41.058% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $573.2M, which are larger than DBV Technologies SA quarterly revenues of --. argenx SE's net income of $91.4M is higher than DBV Technologies SA's net income of -$30.4M. Notably, argenx SE's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 20.72x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

NewAmsterdam Pharma Co NV has a net margin of 15.95% compared to argenx SE's net margin of -57.19%. argenx SE's return on equity of -6.01% beat NewAmsterdam Pharma Co NV's return on equity of -51.66%.

argenx SE has a consensus price target of $655.15, signalling upside risk potential of 3.66%. On the other hand NewAmsterdam Pharma Co NV has an analysts' consensus of $43.16 which suggests that it could grow by 64.55%. Given that NewAmsterdam Pharma Co NV has higher upside potential than argenx SE, analysts believe NewAmsterdam Pharma Co NV is more attractive than argenx SE.

argenx SE has a beta of 0.589, which suggesting that the stock is 41.058% less volatile than S&P 500. In comparison NewAmsterdam Pharma Co NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NewAmsterdam Pharma Co NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. NewAmsterdam Pharma Co NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $573.2M, which are larger than NewAmsterdam Pharma Co NV quarterly revenues of $29.1M. argenx SE's net income of $91.4M is higher than NewAmsterdam Pharma Co NV's net income of -$16.6M. Notably, argenx SE's price-to-earnings ratio is -- while NewAmsterdam Pharma Co NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 20.72x versus 70.33x for NewAmsterdam Pharma Co NV. Usually stocks with elevated PS ratios are considered overvalued.

ProQR Therapeutics NV has a net margin of 15.95% compared to argenx SE's net margin of -210.98%. argenx SE's return on equity of -6.01% beat ProQR Therapeutics NV's return on equity of -66.59%.

argenx SE has a consensus price target of $655.15, signalling upside risk potential of 3.66%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $4.10 which suggests that it could grow by 198.51%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.

argenx SE has a beta of 0.589, which suggesting that the stock is 41.058% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.240, suggesting its less volatile than the S&P 500 by 75.965%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $573.2M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.2M. argenx SE's net income of $91.4M is higher than ProQR Therapeutics NV's net income of -$8.9M. Notably, argenx SE's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 20.72x versus 11.27x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.

uniQure NV has a net margin of 15.95% compared to argenx SE's net margin of -1940.45%. argenx SE's return on equity of -6.01% beat uniQure NV's return on equity of -154.29%.

argenx SE has a consensus price target of $655.15, signalling upside risk potential of 3.66%. On the other hand uniQure NV has an analysts' consensus of $30.72 which suggests that it could grow by 73.29%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.

argenx SE has a beta of 0.589, which suggesting that the stock is 41.058% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.539%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $573.2M, which are larger than uniQure NV quarterly revenues of $2.3M. argenx SE's net income of $91.4M is higher than uniQure NV's net income of -$44.4M. Notably, argenx SE's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 20.72x versus 30.01x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.